Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5071034 | 0.85 | LMNA (0.51) | KMT2AMEN1SMN1; SMN2LMNAHPGD | |
| SCHEMBL18101800 | 0.82 | PDE4B (0.42) | KMT2AMEN1HPGDNPC1RAB9A | |
| SCHEMBL10827630 | 0.81 | MEN1 (0.45) | KMT2AMEN1SMN1; SMN2LMNAHPGD | |
| SCHEMBL2281345 | 0.80 | SMN1; SMN2 (0.60) | KMT2AMEN1SMN1; SMN2LMNAHPGD | |
| SCHEMBL1186911 | 0.80 | MEN1 (0.52) | KMT2AMEN1SMN1; SMN2LMNANPC1 | |
| SCHEMBL15654561 | 0.80 | RAB9A (0.53) | KMT2AMEN1LMNAHPGDNPC1 | |
| SCHEMBL7860591 | 0.80 | MEN1 (0.45) | KMT2AMEN1SMN1; SMN2LMNANPC1 | |
| SCHEMBL10827795 | 0.79 | MEN1 (0.43) | KMT2AMEN1SMN1; SMN2LMNAHPGD | |
| SCHEMBL10016275 | 0.79 | KMT2A (0.46) | KMT2AMEN1SMN1; SMN2LMNAHPGD | |
| SCHEMBL18101745 | 0.78 | PARP10 (0.47) | KMT2AMEN1HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, UGCG, GBA2 | KMT2A 4264/4885MEN1 3369/4885SMN1; SMN2 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.